Clinical Trials | January 12, 2026
Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
_256_384.jpg)
Glenmark released Picture Post Cards on World Vitiligo Day
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
The Institute is catering the health needs of the surrounding population with ever-increasing OPD every year along with special OPDs like mother & Child OPD, and LSD clinic
Subscribe To Our Newsletter & Stay Updated
